APEX-BP: Resistant Hypertension Triple-Therapy Trial

Assessing a novel aldosterone synthase inhibitor in adults whose blood pressure remains uncontrolled despite three or more antihypertensive medications.

Key eligibility criteria

• Adults 18–85 years
• Seated SBP ≥ 140 mmHg
• On ≥ 3 BP medications
• No secondary hypertension

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.